- Home
- Investor & Media
- In the News
Article
Recce to expand Phase II trial for diabetic foot infections
Published 22 Apr 2025
Article
Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial
Published 03 Apr 2025
Article
Synthetic Gel Shows Utility Across ABSSSI, Company Sees Other Indications
Published 06 Mar 2025
Article
Australian biotech points to potential superbug use as gel treats skin infections in phase 2 trial
Published 20 Feb 2025
Article
Recce soars on phase II skin infection trial results
Published 17 Feb 2025
Article
Recce Pharmaceuticals doses all patients in phase II skin infection trial
Published 29 Jan 2025
Article
Recce Pharmaceuticals doses all patients in Phase 2 clinical trial of RECCE® 327 topical gel for skin infections
Published 21 Jan 2025
Article
Recce gets Indonesian nod for phase III trial of diabetic foot infection treatment
Published 09 Dec 2024
Article
Complete patent protection for 2 Recce anti-infective treatments
Published 26 Nov 2024
Article
Recce green lit to begin dosing in registrational Phase 3 trial for diabetic foot infections
Published 11 Nov 2024
Article
Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!
Published 16 Oct 2024
Article
Recce’s Phase 2 trial for skin infections hits midway recruitment milestone
Published 09 Oct 2024
Article
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Published 02 Oct 2024
Article
Recce Pharmaceuticals Advances Antibiotic Development to Combat Antimicrobial Resistance
Published 09 Sep 2024
Article
Recce’s reconnaissance against superbug – infiltrate, eliminate, escape undetected
Published 09 Sep 2024
Article
Recce Pharmaceuticals Delivers the Opening Address at World Antimicrobial Resistance Congress 2024
Published 06 Sep 2024
Article
Recce Pharmaceuticals more than doubles SPP target with A$4.4 million taking raise proceeds to A$12.4 million
Published 05 Aug 2024
Article
Recce scores US$2M deal from US Department of Defense for burn wound infections gel
Published 16 Jul 2024
Article
Recce Pharmaceuticals granted US$2 million from US Department of Defense for RECCE® 327 Gel
Published 15 Jul 2024
Article
Recce Pharmaceuticals reports positive data from Phase 1/2 UTI/urosepsis rapid infusion clinical trial of RECCE® 327
Published 28 Jun 2024
Article
Recce Starts Phase 2 R327 Gel trial for bacterial skin infections
Published 25 Jun 2024
Article
Recce Pharmaceuticals lands WHO Antibacterial Products in Clinical Development listing for RECCE® 327
Published 18 Jun 2024
Article
Recce completes cohort dosing for Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial with fastest infusion times yet; key safety review inbound
Published 12 Jun 2024
Article
Recce wraps up IV UTI trial with fastest infusion times yet; key safety review inbound
Published 11 Jun 2024
Article
Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market
Published 27 May 2024
Article
Recce Pharma heading closer to full efficacy data for flagship R327
Published 15 May 2024
Article
Recce Pharmaceuticals makes breakthrough in lung infection treatment with nebulised RECCE® 327
Published 09 May 2024
Article
Recce Pharma picks up Chinese patent for anti-infective drugs
Published 07 May 2024
Article
Recce Pharmaceuticals up 6% on new antibiotic production milestone
Published 16 Apr 2024
Article
Recce Pharmaceuticals selected to participate in UK Government Innovation Agency’s AMR Mission 2024
Published 11 Apr 2024
Article
Recce gearing up for Indonesian trials; US DOD looking at R327 burn gel
Published 09 Apr 2024
Article
Recce gearing up for Indonesian trials; US DOD looking at R327 burn gel
Published 08 Apr 2024
Article
Recce Pharmaceuticals inks new patent for flagship drug in Israel
Published 03 Apr 2024
Article
Recce reaches testing milestone for UTI, Uroseptis antibiotic
Published 22 Mar 2024
Article
Recce Pharmaceuticals hits major milestone in R327 clinical trial for UTI/urosepsis
Published 18 Mar 2024
Article
Recce reaches testing milestone for UTI, Urosepsis antibiotic
Published 17 Mar 2024
Article
Recce Pharma (ASX:RCE) kicks-off dosing for next cohort of UTI trial
Published 13 Mar 2024
Article
Recce Pharmaceuticals secures AUD$11.18M from Endpoints Capital
Published 13 Mar 2024
Article
Biotech around the World: The Low-Down on the Land Down Under
Published 03 Mar 2024
Article
Recce Pharmaceuticals leads the way in collaborative Anti-Infective research
Published 27 Feb 2024
Article
Recce Pharmaceuticals wins safety approval to expand wound infection trial
Published 26 Feb 2024
Article
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
Published 15 Feb 2024
Article
Recce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Program
Published 08 Feb 2024
Article
Recce Pharmaceuticals teams with leading Indonesian biomed company for anti-infective push
Published 06 Feb 2024
Article
Recce Pharmaceuticals to expand diabetes foot infection trial as results prove strong
Published 28 Jan 2024
Article
Recce Pharmaceuticals to expand diabetes foot infection trial as results prove strong
Published 18 Jan 2024
Article
Revolutionary Antibiotic-Resistant Gonorrhea Treatment: A Possible Breakthrough with Recce 327
Published 11 Jan 2024
Article
4 Biotech Executives Share Strategies Behind Successful Fund Raises
Published 08 Jan 2024
Article
Recce Pharmaceuticals higher on positive efficacy data in Murdoch Children’s Research Institute UTI study
Published 08 Jan 2024
Article
Recce Pharmaceuticals — Landmark commitment helps fund R&D costs
Published 22 Dec 2023
Article
Recce secures Australia’s largest-ever $11m Advanced Overseas R&D Finding
Published 20 Dec 2023
Article
Recce Pharmaceuticals awarded A$11 million Advanced Overseas Finding for anti-viral R&D costs
Published 17 Dec 2023
Article
Recce Pharmaceuticals awarded $43.7 million Advanced Overseas Finding for synthetic anti-infective development program
Published 15 Dec 2023
Article
Recce Pharmaceuticals lead anti-infective R327 shows promise against deadly STD in latest animal study
Published 14 Dec 2023
Article
Recce Pharmaceuticals wins Canadian patent for flagship anti-infectives
Published 23 Nov 2023
Article
Recce Pharmaceuticals doses first patients over 15 minutes in R327 UTI/urosepsis trial
Published 07 Nov 2023
Article
Recce Pharmaceuticals completes dosing of first subjects at faster infusion rate in RECCE® 327 clinical trial
Published 07 Nov 2023
Article
Recce Pharmaceuticals presents at Ord Minnett Healthcare Forum
Published 01 Nov 2023
Article
Recce Pharma welcomes approval for faster RECCE327 infusion rate
Published 25 Oct 2023
Article
Recce Pharmaceuticals accelerates R327 trial for UTI patients with faster infusion rate approval
Published 24 Oct 2023
Article
Busiest quarter for Recce Pharmaceuticals: Cashed up for next phases of drug development
Published 23 Oct 2023
Article
Recce Pharma says commercial potential of its anti-infectives is gaining recognition
Published 11 Oct 2023
Article
Recce Pharmaceuticals raise to progress advanced anti-infective
Published 09 Oct 2023
Article
Global fund takes stake in Recce as synthetic antibiotic developer raises $11m
Published 06 Oct 2023
Article
Recce Pharmaceuticals raises further funds to progress trials from entitlement shortfall
Published 06 Oct 2023
Article
Recce Pharmaceuticals advances anti-infective development and clinical trials in FY23
Published 02 Oct 2023
Article
Recce Pharmaceuticals (ASX:RCE) completes cohort dosing in UTI rapid infusion trial
Published 22 Sep 2023
Article
Recce Pharmaceuticals (ASX:RCE) paves its way to commercialisation with breakthrough antibiotic, R327
Published 20 Sep 2023
Article
Recce Pharmaceuticals (ASX:RCE) receives green light for higher dose in rapid infusion phase I/II UTI trial
Published 28 Aug 2023
Article
Recce Pharmaceuticals — R327 progressing in rapid infusion study
Published 24 Aug 2023
Article
Recce Pharmaceuticals (ASX:RCE) doses phase I/II patients in R327 diabetic foot infection trial
Published 22 Aug 2023
Article
Recce Pharmaceuticals (ASX:RCE) concludes stage one analysis of phase I/II R327 topical trial for burn wounds
Published 21 Aug 2023
Article
Recce Pharmaceuticals’ (ASX:RCE) new R327G shows positive response in treatment of antibiotic-resistant infections
Published 08 Aug 2023
Article
Recce Pharmaceuticals awarded Australian patent for lead anti-infectives
Published 04 Aug 2023
Article
Recce Pharmaceuticals (ASX:RCE) charges on with phase I/II UTI trial ahead of schedule
Published 24 Jul 2023
Article
Recce Pharmaceuticals (ASX:RCE) reports “positive” results from phase one R327 clinical trial
Published 19 Jul 2023
Article
Recce Pharmaceuticals verifies positive Phase 1 data from R327 intravenous study
Published 19 Jul 2023
Article
Recce Pharmaceuticals receives A$801,604 in R&D rebate advance
Published 12 Jul 2023
Article
Recce Pharmaceuticals — Gearing up for more R327 studies
Published 11 Jul 2023
Article
Recce Pharmaceuticals (ASX:RCE) kicks off phase I/II UTI trial
Published 10 Jul 2023
Article
Recce Pharmaceuticals lands ethics approval for expanded UTI studies
Published 30 Jun 2023
Article
Recce Pharmaceuticals receives Ethics Approval to expand R327 Faster Infusion, Phase I/II Clinical Trial
Published 29 Jun 2023
Article
Recce Pharmaceuticals (ASX:RCE) gains ethics approval to expand phase I/II trial of R327
Published 29 Jun 2023
Article
Recce Pharmaceuticals recruits outpatient nurses to drive “largest in Australia” diabetic foot infection clinical trial
Published 29 May 2023
Article
Recce Pharmaceuticals (ASX:RCE) appoints outpatient nurses from Ascott
Published 29 May 2023
Article
Recce Pharmaceuticals (ASX:RCE) secures sponsorship to attend BIO Korea 2023
Published 08 May 2023
Article
Recce Pharmaceuticals (ASX:RCE) receives ‘intent to grant’ Patent Family 4 for anti-infectives
Published 11 Apr 2023
Article
Recce Pharmaceuticals (ASX:RCE) selects CMAX for phase I/II UTI clinical trial
Published 20 Feb 2023
Article
Recce Pharmaceuticals boosts finances with A$6.21 million in R&D rebate payments
Published 25 Jan 2023
Article
For this pharma boss, fishing is an experience in positivity
Published 16 Jan 2023
Article
Recce Pharmaceuticals (ASX:RCE) granted notification of intent for Australian patent
Published 10 Jan 2023
Article
ASX:RCE
Published 12 Apr 2023
Recce Pharmaceuticals Ltd attracts $1.8 million as it moves toward human clinical trials Recce Pharmaceuticals Ltd (ASX:RCE) has raised about $1.8 million from sophisticated and institutional investors...
Article
Recce Pharmaceuticals locks
Published 12 Apr 2023
In US patent for synthetic antibiotic to target growing superbug problem Recce Pharmaceuticals (ASX: RCE) has locked-in a US patent for its broad-spectrum synthetic antibiotics, paving the way for the...
Article
Director Trades
Published 12 Apr 2023
A millennial director put his $100k into his own company rather than a house deposit It was millionaire’s row last week in small cap land, with four multi-million dollar trades and one that was pretty close...
Article
Health & Biotech
Published 12 Apr 2023
The biotech veteran chasing a billion-dollar pot of gold He was famously worth over $130 million — on paper at least — when he was running Chemeq, which blew itsel up a decade ago after he left.
Article
Health & Biotech
Published 12 Apr 2023
Why this 29-year-old investor took a six-figure stake in a $17m biotech company I prefer to have my money be working for me,” he tells Stockhead. “I don’t want it to be at the beck and call of Trump having...
Article
Sky Business News
Published 12 Apr 2023
Interview with Peter Switzer One of the worrying trends in hospitals are superbugs, raising question marks over the efficacy of antibiotics. Listed company Recce target is targeting this issue ..
Article
S&P Global
Published 12 Apr 2023
Small companies play big role in search for superbug killers Superbugs are quickly becoming a top health concern, yet there has been a roughly 30-year dry spell in antibiotic molecule discovery...
Article
The West Australian
Published 12 Apr 2023
WA tests synthetic antibiotic A Perth-based pharmaceutical research company is a step closer to developing a new class of synthetic antibiotics to overcome superbugs. Recce Limited has started ...
Article
The Australian
Published 12 Apr 2023
Australia’s Recce strives for immune-proof super-antibiotic Introductory offers to be billed as follows: The Australian Digital Subscription costs 50c per day, billed monthly (min cost up...
Article
BioWorld
Published 12 Apr 2023
Recce nears clinic with ‘master key’ antibiotic to take on superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based...
Article
Fighting Antibiotic Resistance
Published 12 Apr 2023
The world needs new classes of antibiotics Antibiotics The world needs new classes of antibiotics Antibiotics are used as our frontline treatment...
Article
Nature Biopharma
Published 12 Apr 2023
New class of synthetic antibiotics set to tackle superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based...
Article
Coronavirus crisis
Published 12 Apr 2023
Recce Pharmaceuticals is among dozens of WA-founded biotech companies that are making serious waves in the medical research sector, with COVID-19 the latest disease in its sights...
Article
The Australian - Research Special Report 2020
Published 12 Apr 2023
A revolutionary approach to medicine: synthetic anti-Infectives Anti-infectives are used as our frontline treatment for everyday and life threatening bacteria and viral infections…
Article
Pharmafiles 2020: Synthetic Anti-Infectives
Published 12 Apr 2023
AMR is a ticking time bomb argues Recce CEO James Graham...
Article
H.C. Wainwright Global Life Sciences Conference
Published 12 Apr 2023
Click here for full Press Release and Presentation
Article
AusBiotech Journal 2020 Vol 30
Published 12 Apr 2023
A NEW CLASS OF ANTIBIOTICS
Article
AusBiotech Journal 2020 Vol 30
Published 12 Apr 2023
ADVANCING THE ‘ARMS RACE’ against antibiotic-resistant superbugs
Article
PharmaShots Interview w Recce CEO James Graham
Published 12 Apr 2023
James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds.
Article
AusBiotech Journal 2021 Vol 31
Published 12 Apr 2023
A REVOLUTIONARY APPROACH against antimicrobial resistance
Article
Recce tapping European investor interest
Published 12 Apr 2023
Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.
Article
Recce tapping European investor interest
Published 12 Apr 2023
Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.
Article
Proactive Investors - The smart money in medicine: the silent pandemic
Published 12 Apr 2023
Recce Pharmaceuticals is working on a solution.